After treatment cessation at week 26, some weight regain was observed by the week 32 follow-up visit
Furthermore, we observed a significant decrease in the branched-chain amino acids, valine and isoleucine, and a depletion in glutamate and cysteine levels
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: A phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
MitoCur-1 induces ferroptosis to reverse vemurafenib resistance in melanoma through inhibition of USP14
What to Expect in Month 2 Peak nausea: Weeks 6-8 worst for most patients, especially mornings Food aversions: Foods you loved suddenly repulsive (especially meat, coffee) Early satiety: Feel full after 3-4 bites, physical discomfort if you push it Fatigue increases: Combination of medication adjustment and reduced calorie intake Bowel unpredictability: Constipation one day, diarrhea the next Mental fog: Some patients report difficulty concentrating Research from the New England Journal of Medicine on incretin therapies shows this peak-and-resolution pattern is universal across GLP-1 and GIP agonists
